New research reveals semaglutide, the active ingredient in Wegovy, shows promise in treating metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease affecting millions. The study indicates significant improvements in liver health among participants, leading to hopes for FDA approval.
A new study reveals that combinations of common food additives may increase the risk of Type 2 diabetes. Researchers analyzed data from over 108,000 adults, highlighting specific additive mixtures linked to health risks.
Recent research suggests that Ozempic and similar GLP-1 drugs may lower the risk of dementia in those with type 2 diabetes. Discover how these drugs are being tested for dementia prevention!
